Traders should monitor FDA acceptance and review timeline under RTOR, upcoming medical conference data presentation, and potential near-term catalysts from AdvSM NDA submission expected in first half of 2026. Positive regulatory response could drive significant upside.
Price Chart
Executive Summary
Cogent Biosciences announced the submission of a New Drug Application (NDA) for bezuclastinib in second-line GIST under the FDA's RTOR program, based on positive Phase 3 PEAK trial results showing a 50% reduction in progression risk and 16.5-month median PFS. The drug combination also demonstrated a 46% objective response rate, significantly outperforming sunitinib monotherapy.
Key Facts
- Submitted NDA for bezuclastinib in imatinib-resistant GIST under FDA's Real-Time Oncology Review (RTOR) program
- Phase 3 PEAK trial showed 50% reduction in risk of progression or death (HR 0.50) vs sunitinib monotherapy
- Median PFS of 16.5 months with bezuclastinib combination vs 9.2 months for sunitinib alone
- Objective response rate (ORR) of 46% vs 26% in control arm
- Bezuclastinib previously granted Breakthrough Therapy Designation by FDA
- Full data to be presented at a major medical meeting in first half of 2026
- Company plans to initiate Phase 2 trial in first-line GIST patients with exon 9 mutations this quarter
Financial Impact
Potential blockbuster revenue if approved; no direct financial figures disclosed but clinical results support high commercial upside
Risk Factors
- FDA may not approve the NDA or may require additional data
- Immature overall survival data leaves long-term efficacy uncertain
- Recent insider selling of $242.6M in the past 30 days raises potential concern about confidence in near-term prospects
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3266534 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Aug 10, 2026 7w ago | Press Release | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Aug 9, 2026 7w ago | Institutional Cluster | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Jun 12, 2026 16w ago | Press Release | $33.10 $38.87 | ▲ +17.43% | ▲ +15.65% | $31.02 (−6.28%) |
Jun 12, 2026 16w ago | Press Release | $33.10 $38.87 | ▲ +17.43% | ▲ +15.65% | $31.02 (−6.28%) |
May 30, 2026 17w ago | Press Release | $34.81 $38.70 | ▲ +11.18% | ▲ +12.47% | $31.02 (−10.89%) |
May 28, 2026 18w ago | Press Release | $35.38 $38.10 | ▲ +7.69% | ▲ +10.83% | $31.02 (−12.32%) |
May 5, 2026 21w ago | 8-K | $36.98 $32.76 | ▼ −11.41% | ▼ −16.37% | $31.02 (−16.12%) |
Apr 17, 2026 24w ago | Press Release | $37.25 $34.19 | ▼ −8.21% | ▼ −13.59% | $31.02 (−16.72%) |
Apr 1, 2026 26w ago | Press Release | $35.24 $35.87 | ▲ +1.79% | ▼ −7.93% | $31.02 (−11.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access